Cartalax
Khavinson cartilage / connective-tissue bioregulator
Overview
Cartalax is a Khavinson-class short-peptide bioregulator positioned within the Khavinson framework as the cartilage and connective-tissue regulatory peptide, targeting chondrocyte gene-expression programs and connective-tissue maintenance pathways under the shared hypothesis that short tissue-specific peptides act as endogenous bioregulators in their target tissues. The cartilage-tissue positioning makes Cartalax relevant to research workflows studying joint health, chondrocyte biology, and connective-tissue regeneration models. Lyochem supplies Cartalax as a lyophilized 20 mg vial at ≥99.0% HPLC purity. As with the rest of the Khavinson class, CAS is not consistently registered across suppliers and identity is established via sequence verification on the batch COA. The exact sequence varies by supplier source within the Khavinson framework; buyers should treat Cartalax as a class designation and confirm the sequence matches their reference protocol via COA at batch receipt.
Who buys this, and why
Khavinson short bioregulators — Admax, Cortagen, Cartalax, Cardiogen, Bronchogen, Crystagen, Prostamax, Vesugen — ship to research labs replicating Russian-school protocols or running comparative tissue-specific peptide-bioregulator studies. The published literature base for this class is concentrated in Russian-language sources; buyers should expect to consult that literature directly for protocol selection. Analytical-packet expectations are the same as any other lyophilised research peptide.
Primary buyer fit: academic and contract research laboratories.
Specifications
- CAS
- (verification pending, please confirm via COA)
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 20 mg
- MOQ
- On request
- Lead time
- 14–21 days
- Storage
- -20°C, protect from light
Documentation available on request
- Lot-specific Certificate of Analysis (CoA)
- RP-HPLC chromatogram with peak integration
- ESI-MS identity confirmation (±0.5 Da)
- Sequence verification by LC-MS/MS
- Water content by Karl Fischer
- SDS / MSDS
- Source-literature pointer (Russian-language references on request)
- Stability at −20 °C across 12 months
- Sequence ladder available on request
Regulatory note
Khavinson bioregulator; CAS commonly not registered. Confirm sequence and identity per batch COA.
Frequently asked questions
What's the cartilage-tissue research context for Cartalax?▾
Cartalax is positioned within the Khavinson framework as a chondrocyte and connective-tissue regulatory peptide, hypothesized to support cartilage maintenance and joint-tissue gene-expression programs. Published Khavinson-school research on Cartalax focuses on animal models of joint inflammation, age-related cartilage degeneration, and tissue-repair after injury, with the mechanism hypothesis centered on bioregulatory effects on chondrocyte cell-cycle and matrix-protein expression. As with the rest of the Khavinson class, the Western peer-reviewed evidence base is limited, and buyers should reference the original Russian-language publications for protocol design rather than treating Cartalax as a clinically-validated cartilage therapeutic.
How does Cartalax compare with Western-developed joint-cartilage research peptides like BPC-157?▾
Cartalax and BPC-157 occupy different layers of the joint-tissue research landscape. BPC-157 is a Western-developed 15-amino-acid peptide with a substantial published mechanism-of-action literature in Western peer-reviewed journals, and is on the FDA PCAC agenda for 503A bulks-list consideration, it has more regulatory pedigree and broader independent confirmation of its tendon-ligament and connective-tissue effects. Cartalax is a Khavinson-class short peptide with research evidence concentrated in Russian-language sources and limited Western independent replication. For research workflows that need to align with Western clinical or regulatory frameworks, BPC-157 is the more appropriate choice; for buyers specifically studying the Khavinson bioregulator framework or replicating Russian-school protocols, Cartalax is appropriate. The two are not chemically equivalent or pharmacologically interchangeable.
What sample volumes and aliquoting strategy work for Cartalax research at the 20 mg fill size?▾
The standard 20 mg lyophilized fill supports 20-100 single-dose research preparations depending on the dose-per-aliquot target. For typical Khavinson-class research protocols using 200-500 μg per administration, the 20 mg vial supports 40-100 doses. Reconstitution should use isotonic saline or appropriate Khavinson-protocol vehicle at near-neutral pH; the reconstituted solution should be aliquoted into single-use volumes (typically 50-200 μL) and held at -20 °C. Freeze-thaw cycling is the dominant in-lab degradation pathway for short peptides, operational guidance is to thaw an aliquot once for the experiment and discard rather than refreezing. The lyophilized 20 mg vial itself follows the standard 24-month re-test window at -20 °C.
Related peptides